Enochian Biosciences Inc

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall.

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of Seraph Research Institute (SRI), presented data demonstrating daily reduction of Hepatitis B Virus (HBV) until it could no longer be detected by the 8th day. No toxicities to the liver or other tissues were identified. The findings were presented during the prestigious International Liver Conference, and presentations can be found (Link to presentations.)

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

ENOB announced on June 14, 2021, that it has entered into a 29 million registered direct offering, improving its sustainability. Its Pre-IND request for a potential HIV cure has been approved by the FDA.

Enochian Biosciences: A Follow Through For An HIV Cure

The company scores an exclusive license for new potential coronavirus treatment technology.

Why Enochian BioSciences Was a Winner on Monday

General Electric

Raven Industries

Enochian Biosciences Inc (NASDAQ:ENOB) shares are trading higher by 11.7% at $6.48 Monday morning after the company announced it acquired an exclusive license for an innovative technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza. Raven Industries, Inc. (NASDAQ:RAVN) shares are trading higher by 49.3% at $57.67 after CNH Industrial NV (NYSE:CNHI) announced it will acquire the company for $58 per share in cash.

Why Enochian Biosciences, Raven Industries And GE Share Are Trading Higher Today

Enochian BioSciences Inc (NASDAQ: ENOB) has acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza.  The technology is delivered by a nanoparticle, allowing it to either rapidly treat an infection or to wait in ambush for a cell to become infected to prevent (prophylaxis) future infections.

Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology

Request for Pre-Investigator New Drug Meeting to Be Submitted to FDA in Near Term Request for Pre-Investigator New Drug Meeting to Be Submitted to FDA in Near Term

Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology

LOS ANGELES, June 15, 2021 /PRNewswire/ -- (NASDAQ: ENOB) – A promising cure for HIV is moving one step closer to FDA approval. The novel approach to treating HIV in humans using cell therapy, developed by Dr. Serhat Gumrukcu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his team, will move forward to the first stage of the approval process with the FDA – a Pre-Investigational New Drug (Pre-IND) meeting.

Pioneering Research Institute In Los Angeles Moves One Step Closer To Finding A Cure For HIV

The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by 53.97%. This is why it happened.

ENOB Stock Price Increased 53.97%: Why It Happened

The biotech's experimental treatment for HIV could be a game changer.

Here's Why Enochian BioSciences Stock Skyrocketed Today

LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it has entered into a definitive securities purchase agreement with several institutional investors for the issuance and sale of an aggregate of 3,866,667 shares of its common stock at a purchase price of $7.50 per share of common stock a registered direct offering priced at-the-market under Nasdaq rules. The registered direct offering is expected to close on or about June 16, 2021, subject to the satisfaction of customary closing conditions.

Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Shares of ENOB stock are taking off on Monday after Enochain Biosciences received FDA acceptance for its vital HIV treatment. The post ENOB Stock: The HIV Treatment News That Has Enochain Biosciences Skyrocketing Today appeared first on InvestorPlace.

ENOB Stock: The HIV Treatment News That Has Enochain Biosciences Skyrocketing Today

The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by over 140% pre-market. These are the details.

ENOB Stock Price: Over 140% Increase Pre-Market Details

Globalstar

MediaCo Holding Inc.

Making a penny stocks watchlist this week? Check these 3 small-caps out The post Hot Penny Stocks For Your Weekly Watchlist in June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks For Your Weekly Watchlist in June

The FDA has accepted Enochian BioSciences Inc's (NASDAQ: ENOB) pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV. Written comments are expected this Fall.

Why Is Enochian BioSciences (ENOB) Stock Surging Today?

LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV. Written comments are expected this Fall.

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure

LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release of preliminary data relating to the use of a novel cell therapy approach in controlling human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of the Seraph Research Institute (SRI), presented the findings at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Presentation can be found at https://www.enochianbio.com/about-us/collaborations/

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

LOS ANGELES, May 12, 2021 /PRNewswire/ -- (NASDAQ: ENOB) –  A novel approach to HIV cell therapy developed by Dr. Serhat Gumrukçu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his team was presented yesterday as a new approach to treating HIV in humans. The research findings and developments were presented at the 2021 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) to thousands of industry attendees.

A Promising Approach To HIV Cell Therapy, With Exciting Preliminary Results, Was Presented Recently At The Leading Conference On Gene And Cell Therapy

The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) has increased by over 40% pre-market. This is why it happened.

ENOB Stock Price Increases Over 40% Pre-Market: Why It Happened

LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. The important findings were published today, in the peer-reviewed American Journal of Case Reports https://www.amjcaserep.com/abstract/indexMobile/idArt/931030 .

Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy

LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.

Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference

LOS ANGELES, Sept.  10, 2020  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) −  Enochian BioSciences , a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors on its innovative HIV, Hepatitis B and Oncology platforms at the H.C. Wainwright 22nd Annual Global Investment Conference.

Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference

Shares of Enochian Biosciences Inc (NASDAQ: ENOB) were trading more than 75% higher Monday in reaction to the company's announcement regarding a positive FDA meeting regarding its HIV candidate.

Here's Why Small-Cap Biopharma Enochian Is Surging Higher

Enochian BioSciences Inc. (NASDAQ: ENOB) shares more than doubled to start out the week after the company received a critical update from the U.S.

Enochian Bio’s HIV Treatment Is on Its Way With the FDA

Company encouraged by strong alignment with views of FDA’s CBER regarding ENOB-HV-01  LOS ANGELES, June  08, 2020  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Initial Targeted Engagement for Regulatory Advice (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT).  The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01. ENOB-HV-01 is a novel approach to autologous stem cell transplantation, with the potential to cure HIV by increasing engraftment of gene-modified cells that are resistant to HIV infection.  Failure to achieve engraftment has limited the success of other attempts to cure HIV with autologous transplantation.

News for Enochian Biosciences Inc Stock (ENOB)